The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Oncogene Knockdown via Active Loading of Small RNAs into Extracellular Vesicles by Sonication
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Methods such as plasmid transfection, saturated solution incubation, sonication, and electroporation can be used to load drugs into EVs.
“Depending on the nature of the drug, methods such as plasmid transfection [38], saturated solution incubation [39], sonication [40], and electroporation [16] can be used to load drugs into EVs.”
From Engineered Extracellular Vesicles Loaded with MiR-100-5p Antagonist Selectively Target the Lesioned Region to Promote Recovery from Brain Damage (2025) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Wiklander, O. P. B., Nordin, J. Z., O'Loughlin, A., Gustafsson, Y., Corso, G., Mäger, I., Vader, P., Lee, Y., Sork, H., Seow, Y., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.26316 · Cited by 1,730
Flagged first, then by citations
Research works printed but not linked: 33
- Alvarez-Erviti, L., Y. Seow, H. Yin, C. Betts, S. Lakhal, and M. J. Wood. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29:341–345, 2011. · DOI · Paper page
- Andaloussi, E. L., I. Mager, X. O. Breakefield, and M. J. Wood. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12:347–357, 2013. · DOI · Paper page
- Arteaga, C. L., M. X. Sliwkowski, C. K. Osborne, E. A. Perez, F. Puglisi, and L. Gianni. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9:16–32, 2012. · DOI
- Baselga, J., and S. M. Swain. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer. 9:463–475, 2009. · DOI
- Blenkiron, C., and E. A. Miska. miRNAs in cancer: approaches, aetiology, diagnostics and therapy. Hum. Mol. Genet. 16(Spec No 1):R106–R113, 2007. · DOI
- Bumcrot, D., M. Manoharan, V. Koteliansky, and D. W. Sah. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2:711–719, 2006. · DOI
- Choudhury, A., J. Charo, S. K. Parapuram, R. C. Hunt, D. M. Hunt, B. Seliger, and R. Kiessling. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int. J. Cancer. 108:71–77, 2004. · DOI
- Coelho, T., D. Adams, A. Silva, P. Lozeron, P. N. Hawkins, T. Mant, J. Perez, J. Chiesa, S. Warrington, E. Tranter, M. Munisamy, R. Falzone, J. Harrop, J. Cehelsky, B. R. Bettencourt, M. Geissler, J. S. Butler, A. Sehgal, R. E. Meyers, Q. Chen, T. Borland, R. M. Hutabarat, V. A. Clausen, R. Alvarez, K. Fitzgerald, C. Gamba-Vitalo, S. V. Nochur, A. K. Vaishnaw, D. W. Sah, J. A. Gollob, and O. B. Suhr. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369:819–829, 2013. · DOI · Paper page
- Cooper, J. M., P. B. Wiklander, J. Z. Nordin, R. Al-Shawi, M. J. Wood, M. Vithlani, A. H. Schapira, J. P. Simons, S. El-Andaloussi, and L. Alvarez-Erviti. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov. Disord. 29:1476–1485, 2014. · DOI
- De Jong, W. H., and P. J. Borm. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed. 3:133–149, 2008. · DOI
- El-Andaloussi, S., Y. Lee, S. Lakhal-Littleton, J. Li, Y. Seow, C. Gardiner, L. Alvarez-Erviti, I. L. Sargent, and M. J. Wood. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat. Protoc. 7:2112–2126, 2012. · DOI
- Esmaeilzadeh-Gharehdaghi, E., A. Amani, M. R. Khoshayand, M. Banan, E. Esmaeilzadeh-Gharehdaghi, M. A. Amini, and M. A. Faramarzi. Chitosan nanoparticles for siRNA delivery: optimization of processing/formulation parameters. Nucleic Acid Ther. 24:420–427, 2014. · DOI
- Faltus, T., J. Yuan, B. Zimmer, A. Kramer, S. Loibl, M. Kaufmann, and K. Strebhardt. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 6:786–795, 2004. · DOI
- Farooqi, A. A., Z. U. Rehman, and J. Muntane. Antisense therapeutics in oncology: current status. Onco Targets Ther. 7:2035–2042, 2014. · DOI
- Gavrilov, K., and W. M. Saltzman. Therapeutic siRNA: principles, challenges, and strategies. Yale J. Biol. Med. 85:187–200, 2012.
- Gyorgy, B., M. E. Hung, X. O. Breakefield, and J. N. Leonard. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu. Rev. Pharmacol. Toxicol. 55:439–464, 2015. · DOI
- Haney, M. J., N. L. Klyachko, Y. Zhao, R. Gupta, E. G. Plotnikova, Z. He, T. Patel, A. Piroyan, M. Sokolsky, A. V. Kabanov, and E. V. Batrakova. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J. Control Release 207:18–30, 2015. · DOI · Paper page
- Kim, M. S., M. J. Haney, Y. Zhao, V. Mahajan, I. Deygen, N. L. Klyachko, E. Inskoe, A. Piroyan, M. Sokolsky, O. Okolie, S. D. Hingtgen, A. V. Kabanov, and E. V. Batrakova. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12(3):655–664, 2016. · DOI
- Kooijmans, S. A., S. Stremersch, K. Braeckmans, S. C. de Smedt, A. Hendrix, M. J. Wood, R. M. Schiffelers, K. Raemdonck, and P. Vader. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J. Control Release 172:229–238, 2013. · DOI · Paper page
- Kundu, A. K., P. K. Chandra, S. Hazari, Y. V. Pramar, S. Dash, and T. K. Mandal. Development and optimization of nanosomal formulations for siRNA delivery to the liver. Eur. J. Pharm. Biopharm. 80:257–267, 2012. · DOI
- Lamichhane, T. N., R. S. Raiker, and S. M. Jay. Exogenous DNA loading into extracellular vesicles via electroporation is size-dependent and enables limited gene delivery. Mol. Pharm. 12:3650–3657, 2015. · DOI
- Lamichhane, T. N., S. Sokic, J. S. Schardt, R. S. Raiker, J. W. Lin, and S. M. Jay. Emerging roles for extracellular vesicles in tissue engineering and regenerative medicine. Tissue Eng. Part B Rev. 21:45–54, 2015. · DOI
- McClorey, G., and M. J. Wood. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr. Opin. Pharmacol. 24:52–58, 2015. · DOI
- Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469–6487, 2007. · DOI
- Munoz, J. L., S. A. Bliss, S. J. Greco, S. H. Ramkissoon, K. L. Ligon, and P. Rameshwar. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol. Ther. Nucleic Acids 2:e126, 2013. · DOI
- Ohno, S., M. Takanashi, K. Sudo, S. Ueda, A. Ishikawa, N. Matsuyama, K. Fujita, T. Mizutani, T. Ohgi, T. Ochiya, N. Gotoh, and M. Kuroda. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21:185–191, 2013. · DOI · Paper page
- Peer, D., and J. Lieberman. Special delivery: targeted therapy with small RNAs. Gene Ther. 18:1127–1133, 2011. · DOI
- Smyth, T., M. Kullberg, N. Malik, P. Smith-Jones, M. W. Graner, and T. J. Anchordoquy. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J. Control Release. 199:145–155, 2015. · DOI
- Tan, W. B., S. Jiang, and Y. Zhang. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 28:1565–1571, 2007. · DOI
- Thiel, K. W., L. I. Hernandez, J. P. Dassie, W. H. Thiel, X. Liu, K. R. Stockdale, A. M. Rothman, F. J. Hernandez, J. O. McNamara, 2nd, and P. H. Giangrande. Delivery of chemo-sensitizing siRNAs to HER2 + -breast cancer cells using RNA aptamers. Nucleic Acids Res. 40:6319–6337, 2012. · DOI
- Wichmann, H., A. Guttler, M. Bache, H. Taubert, S. Rot, J. Kessler, A. W. Eckert, M. Kappler, and D. Vordermark. Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells. Strahlenther. Onkol. 191:180–191, 2015. · DOI
- Wittrup, A., and J. Lieberman. Knocking down disease: a progress report on siRNA therapeutics. Nat. Rev. Genet. 16:543–552, 2015. · DOI
- Zhao, D., Y. Sui, and X. Zheng. miR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer. Oncol. Rep. 35:1075–1082, 2016. · DOI
Cited by
Sorted by citations
RNA delivery by extracellular vesicles in mammalian cells and its applications
O’Brien, K., Breyne, K., Ughetto, S., Laurent, L. C., & Breakefield, X. O. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0251-y · Cited by 1,811
Advances in therapeutic applications of extracellular vesicles
Wiklander, O. P. B., Brennan, M. Á., Lötvall, J., Breakefield, X. O., & EL Andaloussi, S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8521 · Cited by 1,039
Recent advances in exosome-mediated nucleic acid delivery for cancer therapy
Zhang, Y., Liu, Q., Zhang, X., Huang, H., Tang, S., Chai, Y., Xu, Z., Li, M., Chen, X., Liu, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01472-z · Cited by 306
Improved Loading of Plasma-Derived Extracellular Vesicles to Encapsulate Antitumor miRNAs
Pomatto, M. A. C., Bussolati, B., D’Antico, S., Ghiotto, S., Tetta, C., Brizzi, M. F., & Camussi, G. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.001 · Cited by 243
Liu, Q., Li, D., Pan, X., & Liang, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02081-0 · Cited by 201
Patel, D. B., Luthers, C. R., Lerman, M. J., Fisher, J. P., & Jay, S. M. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.11.024 · Cited by 152
Self-citationExtracellular Vesicles as an Emerging Frontier in Spinal Cord Injury Pathobiology and Therapy
Dutta, D., Khan, N., Wu, J., & Jay, S. M. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.01.003 · Cited by 112
Self-citationStrategies for the use of Extracellular Vesicles for the Delivery of Therapeutics
Sil, S., Dagur, R. S., Liao, K., Peeples, E. S., Hu, G., Periyasamy, P., & Buch, S. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09873-y · Cited by 109
Extracellular vesicles in cancer nanomedicine
Tarasov, V. V., Svistunov, A. A., Chubarev, V. N., Dostdar, S. A., Sokolov, A. V., Brzecka, A., Sukocheva, O., Neganova, M. E., Klochkov, S. G., Somasundaram, S. G., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.017 · Cited by 97
Current advances in non‐viral gene delivery systems: Liposomes versus extracellular vesicles
Belhadj, Z., Qie, Y., Carney, R. P., Li, Y., & Nie, G. (2023) · BMEMat · doi:10.1002/bmm2.12018 · Cited by 79
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges
Ubanako, P., Mirza, S., Ruff, P., & Penny, C. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1447953 · Cited by 68
Cheng, Y., Gai, C., Zhao, Y., Li, T., Song, Y., Luo, Q., Xin, D., Jiang, Z., Chen, W., Liu, D., et al. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01376-6 · Cited by 5
Metadata
- Authors
- Lamichhane, T. N., Jeyaram, A., Patel, D. B., Parajuli, B., Livingston, N. K., Arumugasaamy, N., Schardt, J. S., & Jay, S. M.
- Venue
- Cellular and Molecular Bioengineering
- Published
- 2016-07-07
- Volume
- 9
- Issue
- 3
- Pages
- 315-324
- ISSN
- 1865-5025
- 1865-5033
- PMC
- PMC5084850
- Cited by
- 347
- References
- 3
- Language
- en
- Funders
- National Heart, Lung, and Blood Institute (R00 HL112905)
- Oak Ridge Associated Universities (Ralph E. Powe Junior Faculty Award)
- University of Maryland Foundation (Tier 1 Seed Grant, UMD-UMB Seed Grant)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
